Regardless of the feasibility and outcome of alternative therapies, at present, there is an increasing interest for salvage re-irradiation of PSMA-detected local relapses even before PSA relapse becomes apparent, especially since early predictors of pending relapse after prostate cancer radiotherapy are emerging (22). This evidence concerns the gene FOLH1 and prostate cancer.